Literature DB >> 16803598

Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.

John-Paul Vermitsky1, Kelly D Earhart, W Lamar Smith, Ramin Homayouni, Thomas D Edlind, P David Rogers.   

Abstract

Candida glabrata emerged in the last decade as a common cause of mucosal and invasive fungal infection, in large part due to its intrinsic or acquired resistance to azole antifungals such as fluconazole. In C. glabrata clinical isolates, the predominant mechanism behind azole resistance is upregulated expression of multidrug transporter genes CDR1 and PDH1. We previously reported that azole-resistant mutants (MIC >or= 64 microg ml(-1)) of strain 66032 (MIC = 16 microg ml(-1)) similarly show coordinate CDR1-PDH1 upregulation, and in one of these (F15) a putative gain-of-function mutation was identified in the single homologue of Saccharomyces cerevisiae transcription factors Pdr1-Pdr3. Here we show that disruption of C. glabrata PDR1 conferred equivalent fluconazole hypersensitivity (MIC = 2 microg ml(-1)) to both F15 and 66032 and eliminated both constitutive and fluconazole-induced CDR1-PDH1 expression. Reintroduction of wild-type or F15 PDR1 fully reversed these effects; together these results demonstrate a role for this gene in both acquired and intrinsic azole resistance. CDR1 disruption had a partial effect, reducing fluconazole trailing in both strains while restoring wild-type susceptibility (MIC = 16 microg ml(-1)) to F15. In an azole-resistant clinical isolate, PDR1 disruption reduced azole MICs eight- to 64-fold with no effect on sensitivity to other antifungals. To extend this analysis, C. glabrata microarrays were generated and used to analyse genome-wide expression in F15 relative to its parent. Homologues of 10 S. cerevisiae genes previously shown to be Pdr1-Pdr3 targets were upregulated (YOR1, RTA1, RSB1, RPN4, YLR346c and YMR102c along with CDR1, PDH1 and PDR1 itself) or downregulated (PDR12); roles for these genes include small molecule transport and transcriptional regulation. However, expression of 99 additional genes was specifically altered in C. glabrata F15; their roles include transport (e.g. QDR2, YBT1), lipid metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA repair (YIM1, MEC3) and cell wall function (MKC7, MNT3). These azole resistance-associated changes could affect C. glabrata tissue-specific virulence; in support of this, we detected differences in F15 oxidant, alcohol and weak acid sensitivities. C. glabrata provides a promising model for studying the genetic basis of multidrug resistance and its impact on virulence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803598     DOI: 10.1111/j.1365-2958.2006.05235.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  97 in total

1.  The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata.

Authors:  Sapan Borah; Raju Shivarathri; Rupinder Kaur
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

2.  Enhanced Efflux Pump Activity in Old Candida glabrata Cells.

Authors:  Somanon Bhattacharya; Bettina C Fries
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 3.  Multidrug resistance in fungi.

Authors:  Kailash Gulshan; W Scott Moye-Rowley
Journal:  Eukaryot Cell       Date:  2007-09-14

4.  Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.

Authors:  Scott E Gygax; John-Paul Vermitsky; Sean G Chadwick; Matthew J Self; Jessica A Zimmerman; Eli Mordechai; Martin E Adelson; Jason P Trama
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

5.  Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Authors:  Sarah G Whaley; Qing Zhang; Kelly E Caudle; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

6.  STB5 is a negative regulator of azole resistance in Candida glabrata.

Authors:  Jason A Noble; Huei-Fung Tsai; Sara D Suffis; Qin Su; Timothy G Myers; John E Bennett
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

7.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

8.  Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering.

Authors:  Dwight Kuo; Kai Tan; Guy Zinman; Timothy Ravasi; Ziv Bar-Joseph; Trey Ideker
Journal:  Genome Biol       Date:  2010-07-23       Impact factor: 13.583

9.  Candida glabrata environmental stress response involves Saccharomyces cerevisiae Msn2/4 orthologous transcription factors.

Authors:  Andreas Roetzer; Christa Gregori; Ann Marie Jennings; Jessica Quintin; Dominique Ferrandon; Geraldine Butler; Karl Kuchler; Gustav Ammerer; Christoph Schüller
Journal:  Mol Microbiol       Date:  2008-06-28       Impact factor: 3.501

10.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.